6533b853fe1ef96bd12abfd4
RESEARCH PRODUCT
A nonrandomized, phase IV trial of FOLFIRI and cetuximab in first-line treatment of metastatic colorectal cancer receiving a predefined skin care and skin prophylaxis aiming to prevent a skin rash.
Markus MoehlerKlaus Maria JostenMichael NeiseCarmen DhensawHolger HebartClaudia LangM. A. WoernsJochen RudiMeinolf KarthausThomas GeerJan WiereckyPeter R. GallePeter EhscheidtMichael HeikeThomas GoehlerThomas FlohrGerrit DingeldeinCarl C. SchimanskiAlexander Schmittelsubject
OncologySkin careCancer Researchmedicine.medical_specialtyCetuximabColorectal cancerbusiness.industrymedicine.diseaseRashPhase IV TrialSurgeryFirst line treatmentOncologyInternal medicinemedicineFOLFIRIOverall survivalmedicine.symptombusinessmedicine.drugdescription
e20724 Background: Anti-EGFR empowered chemotherapeutic regimens resulted in increased overall survival (OS) and response rates (RR). Anti-EGFR induced skin rash occurs in ~ 70% patients, and ~18% ...
year | journal | country | edition | language |
---|---|---|---|---|
2014-05-20 | Journal of Clinical Oncology |